S 48168 (ARM 210) for the Treatment of RYR1-related Myopathies (RYR1-RM)
NCT04141670
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
7
Enrollment
INDUSTRY
Sponsor class
Conditions
RYR-1 Myopathy
Interventions
DRUG:
S48168
Sponsor
RyCarma Therapeutics, Inc.
Collaborators
[object Object]
[object Object]
[object Object]